FEEDS
Impact of Early Insulin Initiation on Glycemic Control in Asian People with Type 2 Diabetes
Paris (ots/PRNewswire) - Two studies presented at World Diabetes Congress 2011 provide further evidence of the benefits to patients of early glycemic control on co-morbidities Sanofi announced today new results from ... weiter zur Pressemitteilung von sanofi-aventis Group
Oral Therapy Teriflunomide (Aubagio?(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Paris (ots/PRNewswire) - - New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress - - U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS - Sanofi and its subsidiary ... weiter zur Pressemitteilung von sanofi-aventis Group
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio?(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Paris (ots/PRNewswire) - - Findings from Two-Year Pivotal Phase III TEMSO Trial Published today in The New England Journal of Medicine - Sanofi and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with ... weiter zur Pressemitteilung von sanofi-aventis Group
More Patients with Type 2 Diabetes Reach HbA[1c] Target with Apidra® on top of Lantus® Than with Twice-daily Aspart Premixed Insulin
Paris (ots/PRNewswire) - - First Randomized Controlled Trial to Show That Basal Plus Regimen Provides more Effective Glycemic Control with Less Hypoglycemia Than with Aspart Premixed Insulin Sanofi announced today data presented at the 47th Annual ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi Announces Nursing Recognition Program to Help Turn Caring Ideas Into Reality
Paris (ots/PRNewswire) - -- Nurses Worldwide are Encouraged to Enter an Exciting Recognition Program Which Showcases Their Creativity and Their Care Solutions/Practice Innovations -- Sanofi announced ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi Pasteur and Merck Vaccines Appoint Dr Jean-Paul Kress, as President of Sanofi Pasteur MSD
Lyon, France (ots/PRNewswire) - - Newcomer's Biopharmaceutical Experience to Further Develop European Joint-Venture - MSD, known as Merck in the United States and Canada , and Sanofi Pasteur, the vaccines division of Sanofi , the two partner ... weiter zur Pressemitteilung von sanofi-aventis Group
New Data Shows Lantus® Activation of Insulin Receptor Comparable to Human Insulin
Paris (ots/PRNewswire) - - Human and in vivo Studies Indicate Lantus(R) Metabolites do not ConferCarcinogenic Potential via IGF-1 Receptor Activation Sanofi announced at the 71st American Diabetes Association Scientific Sessions 2011 the results of ... weiter zur Pressemitteilung von sanofi-aventis Group
Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
Paris (ots/PRNewswire) - Sanofi announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus(R) and/or Apidra(R) with the insulin ... weiter zur Pressemitteilung von sanofi-aventis Group
Prüfsubstanz Semuloparin von Sanofi bei Krebspatienten zu Beginn der Chemotherapie zeigt 64%ige Risikoreduktion lebensbedroher venöser Thromboembolien
Paris (ots/PRNewswire) - - Ergebnisse der für "Best of ASCO 2011" ausgewählten Phase III-SAVE-ONCO-Studie - Bis zu einem Fünftel der Krebspatienten leidet an venöser Thromboembolie und die Chemotherapie erhöht das Risiko noch weiter Sanofi ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event
LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011 (ots/PRNewswire) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group , today will participate in the first international bell-ringing event by a company listed on NYSE ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi Pasteur and International Vaccine Institute Partner Against Dengue
Lyon, France (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis Partners in European Atrial Fibrillation Research Consortium
Paris, November 5 (ots/PRNewswire) - Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation" (EUTRAF), which ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
Lyon, France, November 4 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group , announced today that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur's dengue vaccine, the world's most ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
Paris (ots/PRNewswire) - Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple ... weiter zur Pressemitteilung von sanofi-aventis Group
Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
Paris (ots/PRNewswire) - Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes
Paris (ots/PRNewswire) - Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden. The first pooled analysis using patient-level data from ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis: Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients With Type 2 Diabetes
Paris (ots/PRNewswire) - Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 ... weiter zur Pressemitteilung von sanofi-aventis Group
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Paris (ots/PRNewswire) - Sanofi-aventis announced today that results from the RealiseAF (Real-life global survey evaluating patients with Atrial Fibrillation) registry show that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC ... weiter zur Pressemitteilung von sanofi-aventis Group
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Paris, August 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple ... weiter zur Pressemitteilung von sanofi-aventis Group
Multaq(R) First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
Paris, August 29, 2010 (ots/PRNewswire) - Sanofi aventis announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial Fibrillation (AF) have been released and recommend that Multaq(R) (dronedarone) ... weiter zur Pressemitteilung von sanofi-aventis Group
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Paris, June 7, 2010 (ots/PRNewswire) - Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation
Paris, May 12, 2010 (ots/PRNewswire) - Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis: Multaq(R) Receives Positive Recommendation by NICE in New Appraisal Consultation Document
Paris, March 30, 2010 (ots/PRNewswire) - Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 (ots/PRNewswire) - - First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing ... weiter zur Pressemitteilung von sanofi-aventis Group
Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation
Paris, November 16 (ots/PRNewswire) - - The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) ... weiter zur Pressemitteilung von sanofi-aventis Group
